Dr. Kumar Discusses Study of Ixazomib in Multiple Myeloma

Shaji K. Kumar, MD
Published: Wednesday, Sep 06, 2017



Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses a study of ixazomib (Ninlaro) as maintenance therapy in multiple myeloma.

The current analysis focuses on the long-term outcomes of patients treated with ixazomib in combination with standard doses of lenalidomide (Revlimid) and dexamethasone, initial results of which were published 2 years ago.

The study enrolled 42 patients out of the 66 who did not go to a stem cell transplant but continued therapy with ixazomib, with a median follow-up of 55 months.
 
SELECTED
LANGUAGE


Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses a study of ixazomib (Ninlaro) as maintenance therapy in multiple myeloma.

The current analysis focuses on the long-term outcomes of patients treated with ixazomib in combination with standard doses of lenalidomide (Revlimid) and dexamethasone, initial results of which were published 2 years ago.

The study enrolled 42 patients out of the 66 who did not go to a stem cell transplant but continued therapy with ixazomib, with a median follow-up of 55 months.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x